Technical Analysis for TPST - Tempest Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 3.24 | -0.79% | -0.03 |
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | -0.79% | |
| Narrow Range Bar | Range Contraction | -0.79% | |
| Inside Day | Range Contraction | -0.79% | |
| Wide Bands | Range Expansion | -0.79% | |
| Oversold Stochastic | Weakness | -0.79% | |
| Wide Bands | Range Expansion | -3.16% | |
| Oversold Stochastic | Weakness | -3.16% | |
| MACD Bearish Centerline Cross | Bearish | -2.87% | |
| Wide Bands | Range Expansion | -2.87% | |
| Oversold Stochastic | Weakness | -2.87% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 1 minute ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 3 hours ago |
| Possible NR7 | about 23 hours ago |
| Possible Inside Day | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Tempest Therapeutics, Inc. Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc. operates as a subsidiary of Inception Sciences, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Tumor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.0 |
| 52 Week Low | 0.17 |
| Average Volume | 1,066,333 |
| 200-Day Moving Average | 2.82 |
| 50-Day Moving Average | 3.83 |
| 20-Day Moving Average | 3.94 |
| 10-Day Moving Average | 3.72 |
| Average True Range | 0.42 |
| RSI (14) | 40.48 |
| ADX | 18.97 |
| +DI | 21.46 |
| -DI | 23.56 |
| Chandelier Exit (Long, 3 ATRs) | 4.74 |
| Chandelier Exit (Short, 3 ATRs) | 4.46 |
| Upper Bollinger Bands | 5.14 |
| Lower Bollinger Band | 2.74 |
| Percent B (%b) | 0.22 |
| BandWidth | 60.90 |
| MACD Line | -0.10 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.1202 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.47 | ||||
| Resistance 3 (R3) | 3.47 | 3.40 | 3.43 | ||
| Resistance 2 (R2) | 3.40 | 3.35 | 3.40 | 3.42 | |
| Resistance 1 (R1) | 3.34 | 3.32 | 3.31 | 3.34 | 3.41 |
| Pivot Point | 3.27 | 3.27 | 3.26 | 3.27 | 3.27 |
| Support 1 (S1) | 3.21 | 3.22 | 3.18 | 3.21 | 3.13 |
| Support 2 (S2) | 3.14 | 3.19 | 3.14 | 3.12 | |
| Support 3 (S3) | 3.08 | 3.14 | 3.11 | ||
| Support 4 (S4) | 3.08 |
